Halozyme therapeutics Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Halozyme therapeutics Contact Number

Contact Halozyme

9 hours ago Halozyme.com Show details

858.794.8889Halozyme Therapeutics 11388 Sorrento Valley Road San Diego, CA 92121 Phone: 858.794.8889 Fax: 858.704.8311 Email: [email protected]halozyme.com

1. 11388 Sorrento Valley Rd, San Diego, CA 92121

Category: Contact SupportShow more

Halozyme Therapeutics Crunchbase Company Profile & …

1 hours ago Crunchbase.com Show details

858.794.8889Contact Email [email protected]halozyme.com. Phone Number 858.794.8889. Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the insulin, cancer, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the

Founder: Gregory Frost
Location: San Diego, California
Founded: Jul 01, 2007

Category: Contact NumberShow more

Halozyme Overview, News & Competitors ZoomInfo.com

8 hours ago Zoominfo.com Show details

(858) 794-8889Halozyme’s headquarters are in 11388 Sorrento Valley Rd, San Diego, California, 92121, United States What is Halozyme’s phone number? Halozyme’s phone number is (858) 794-8889

Employees: 132
Phone: (858) 794-8889
Location: 11388 Sorrento Valley Rd, San Diego, 92121, California

Category: Contact NumberShow more

Halozyme Therapeutics, Inc. Company Profile San Diego

9 hours ago Dnb.com Show details

(858) 794-8889Company Description: Halozyme Therapeutics is searching for cures through a number of "ologys" by developing treatments for use in endocrinology, oncology, and dermatology fields. It is also creating products for the drug delivery market. Its Hylenex recombinant is used as an adjuvant for drug and fluid infusions.

Employees: 255
Phone: (858) 794-8889
Location: 11388 Sorrento Valley Rd Ste 200, San Diego, 92121-1345, CA

Category: Contact NumberShow more

Halozyme Therapeutics, Inc. Investor Relations

5 hours ago Ir.halozyme.com Show details

858-704-8122Contact Us. Al Kildani Vice President, Investor Relations & Corporate Communications 858-704-8122 [email protected]halozyme.com [email protected]halozyme.com [email protected]halozyme.com

Category: Contact NumberShow more

Halozyme Therapeutics Biocom California

2 hours ago Biocom.org Show details

Halozyme is a biopharmaceutical company developing and commercializing recombinant human enzymes for the drug delivery, palliative care, oncology, and infertility markets. The company’s portfolio of products is based on intellectual property covering the family of human enzymes known as hyaluronidases.

Category: Contact NumberShow more

Halozyme Therapeutics, Inc. SEC.gov

3 hours ago Sec.gov Show details

(858) 794-8889Our telephone number is (858) 794-8889 and our e-mail address is [email protected]halozyme.com. Additional information about Halozyme can be found on our website, at www.halozyme.com, and in our periodic and current reports filed with the Securities and Exchange Commission (“SEC”).

Category: Contact NumberShow more

ENHANZE Halozyme

9 hours ago Halozyme.com Show details

Halozyme’s primary technology is based on its proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) that degrades hyaluronan, or HA. HA is a glycosaminoglycan, a chain of natural sugars that is a component of normal tissue, such as skin and cartilage. The effects of rHuPH20 are local and transient.

Category: Contact NumberShow more

Halozyme Therapeutics SEC

3 hours ago Sec.gov Show details

Stockholders may recommend individuals for the Nominating and Governance Committee to consider as potential director candidates by submitting the candidate’s name, contact information and biographical information in writing to the “Halozyme Nominating and Governance Committee” c/o Corporate Secretary, 11388 Sorrento Valley Road, San Diego

Category: Contact NumberShow more

Halozyme Therapeutic Beats Earnings Whispers

8 hours ago Earningswhispers.com Show details

Halozyme Therapeutic (HALO) reported 3rd Quarter September 2021 earnings of $0.52 per share on revenue of $115.8 million. The consensus earnings estimate was $0.38 per share on revenue of $107.0 million. The Earnings Whisper number was $0.48 per share. Revenue grew 77.3% on a year-over-year basis. The company also provided guidance above …

Category: Contact NumberShow more

Halozyme, Inc. LinkedIn

9 hours ago Linkedin.com Show details

Halozyme, Inc. 14,109 followers on LinkedIn. At Halozyme we continuously push the pace of innovation. Halozyme is a biopharmaceutical company bringing disruptive solutions to …

Category: Contact NumberShow more

Mark Bubany Halozyme Therapeutics CA USA Database

Just Now Bestdataprovider.com Show details

Mark Bubany is serving as Executive Director, Access and Reimbursement in the Halozyme Therapeutics is an active company headquartered in San Diego, CA in the states of CA.The Halozyme Therapeutics office address is located at San Diego, CA, United States.The company comes under Biotech/Healthcare->BioTech/Drugs industries.

Category: Contact NumberShow more

Halozyme Therapeutics, Inc. Home Facebook

4 hours ago Facebook.com Show details

Halozyme Therapeutics, Inc., San Diego, California. 117 likes. Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly …

Category: Home PhoneShow more

Privacy Policy Hylenex

5 hours ago Hylenex.com Show details

(855-495-3639If you ever decide that you do not wish to receive information from us regarding Hylenex recombinant, contact us at: Halozyme Therapeutics. 11388 Sorrento Valley Road San Diego, CA 92121. If you have any questions, comments, concerns, or complaints about our information practices: call 855-HYLENEX (855-495-3639) fax your inquiry to 800-881-6092

Category: Contact NumberShow more

Halozyme Wikipedia

8 hours ago En.wikipedia.org Show details

Halozyme Therapeutics is an American biotechnology company that develops novel oncology therapies designed to target the tumor microenvironment and licenses a novel drug delivery technology through corporate partnerships.. The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California.

Category: Contact NumberShow more

Halozyme Therapeutics, Inc. Events & Presentations

5 hours ago Ir.halozyme.com Show details

858-704-8122Contact Us. Al Kildani Vice President, Investor Relations & Corporate Communications 858-704-8122 [email protected]halozyme.com [email protected]halozyme.com [email protected]halozyme.com

Category: Contact NumberShow more

Halozyme Therapeutics EquityNet

9 hours ago Equitynet.com Show details

Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the insulin, cancer, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the …

Category: Contact NumberShow more

Home Hylenex

Just Now Hylenex.com Show details

The Market Leader* The Only FDA-Approved Recombinant Human Hyaluronidase #1 prescribed* Preservative-free 24-month shelf life On all major GPO contracts Consistently available Supplied in a convenient 4-pack Made in the USA in a cGMP-compliant facility Over 2 million vials sold Supported by a dedicated sales team Indication: Hylenex® recombinant

Category: Home PhoneShow more

Chemophase Trademark Halozyme Therapeutics, Inc. San

1 hours ago Bizapedia.com Show details

Chemophase is a Trademark by Halozyme Therapeutics, Inc., the address on file for this trademark is 11588 Sorrento Valley Road, Suite 17, San Diego, CA 92121

Category: Contact NumberShow more

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Number of Hedge

2 hours ago Investorshub.advfn.com Show details

Number of Hedge Fund Holders: 23. Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharma technology platform firm. The company has registered a 145% increase in royalties between June and September this year as the sales of Darzalex, an FDA-approved second-line therapy for multiple myeloma, skyrocket. The company is also on the …

Category: Contact NumberShow more

ENHANZE® drug delivery technology: a novel approach to

3 hours ago Ncbi.nlm.nih.gov Show details

ENHANZE ® drug delivery technology is based on the proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20; Halozyme Therapeutics, Inc.) that facilitates the subcutaneous (SC) delivery of co‐administered therapeutics. rHuPH20 works by degrading the glycosaminoglycan hyaluronan (HA), which plays a role in resistance to bulk fluid flow in the …

Category: Tech SupportShow more

DailyMed HYLENEX RECOMBINANT (hyaluronidase human

3 hours ago Dailymed.nlm.nih.gov Show details

HYLENEX recombinant is produced by genetically engineered Chinese Hamster Ovary (CHO) cells containing a DNA plasmid encoding for a soluble fragment of human hyaluronidase (PH20). The purified hyaluronidase glycoprotein contains 447 amino acids with an approximate molecular weight of 61,000 Daltons. HYLENEX recombinant is supplied as a …

Category: Contact NumberShow more

What is Halozyme Therapeutic Valuation? HALO Macroaxis

1 hours ago Macroaxis.com Show details

Halozyme Therapeutic retains a regular Real Value of $42.62 per share. The prevalent price of the firm is $35.48. At this time, the firm appears to be undervalued.Our model calculates the value of Halozyme Therapeutic from evaluating the firm fundamentals such as Current Valuation of 5.7 B, return on asset of 21.72 %, and Return On Equity of 214.94 % as well as inspecting its …

Category: Contact NumberShow more

Current Report Filing (8k)

3 hours ago Ih.advfn.com Show details

HALO Halozyme Therapeutics Incorporated Current Report Filing (8-k) On December 13, 2021, Halozyme Therapeutics, Inc. (the “Company”) announced that Masaru Matsuda will step down from his position as Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary of the Company, effective December 31, 2021, to …

Category: Contact NumberShow more

Commercial Credit Report for Halozyme Therapeutics, Inc

4 hours ago Info.creditriskmonitor.com Show details

(858) 794-8889If you are already a subscriber and want to access the full report, click here. Halozyme Therapeutics, Inc. 11388 Sorrento Valley Rd. Phone: (858) 794-8889. p:858 794-8889. SAN DIEGO, CA 92121-1345 United States. Ticker: HALO. HALO. Business Summary.

Category: Contact NumberShow more

Halozyme Therapeutics Funding, Financials, Valuation

Just Now Crunchbase.com Show details

Halozyme Therapeutics has raised a total of $245M in funding over 5 rounds. Their latest funding was raised on May 14, 2020 from a Post-IPO Equity round. Halozyme Therapeutics is registered under the ticker NASDAQ:HALO . Halozyme Therapeutics is funded by 6 investors. Janssen Biotech and arGEN-X are the most recent investors.

Category: Contact NumberShow more

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus

7 hours ago Marketbeat.com Show details

Halozyme Therapeutics has a twelve month low of $31.79 and a twelve month high of $56.40. The company has a current ratio of 8.99, a quick ratio of 8.50 and a debt-to-equity ratio of 2.79. Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, November 2nd.

Category: Contact NumberShow more

HALOZYME THERAPEUTICS, INC. : HALO Stock Price

4 hours ago Marketscreener.com Show details

Halozyme Therapeutics, Inc. is a biopharma technology platform company. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine its ENHANZE drug delivery technology with the collaborators' compounds. The Company's lead enzyme, rHuPH20, is used to facilitate the delivery of injected

Category: Contact NumberShow more

Top Halozyme Therapeutics Competitors and Alternatives

Just Now Craft.co Show details

Halozyme Therapeutics's main competitors include Partner Therapeutics, Verastem Oncology, Rakuten Medical, Agenus, Blueprint Medicines and Karyopharm Therapeutics. Compare Halozyme Therapeutics to its competitors by revenue, employee growth …

Category: Contact NumberShow more

Statement of Changes in Beneficial Ownership (4)

4 hours ago Ih.advfn.com Show details

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date: 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s

Category: Contact NumberShow more

Hedge Funds Are Betting On Halozyme Therapeutics, Inc

3 hours ago Insidermonkey.com Show details

Halozyme Therapeutics, Inc. (NASDAQ:HALO) was in 23 hedge funds’ portfolios at the end of September. The all time high for this statistic is 26. The all time high for this statistic is …

Category: Contact NumberShow more

argenx and Halozyme enter global collaboration and license

6 hours ago Argenx.com Show details

About Halozyme. Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme contact: Al Kildani. Vice President, Investor Relations and Corporate Communications including uncertainties concerning the number of additional

Category: Contact NumberShow more

Jefferies Financial Group Weighs in on Halozyme

1 hours ago Marketbeat.com Show details

According to data from MarketBeat.com, Halozyme Therapeutics presently has an average rating of "Buy" and a consensus price target of $53.13. Shares of Halozyme Therapeutics stock opened at $36.59 on Wednesday. Halozyme Therapeutics has a 52-week low of $31.79 and a 52-week high of $56.40.

Category: Contact NumberShow more

Rebecca Arlauskas at Halozyme Therapeutics, Inc

4 hours ago Arounddeal.com Show details

Associate Director Quality Assurance at Halozyme Therapeutics, Inc. Rebecca Arlauskas is the Associate Director Quality Assurance at Halozyme Therapeutics, Inc. based in United States. Get Full Access To Rebecca Arlauskas's Info

Category: Contact NumberShow more

Halozyme Therapeutics, Inc. Glancy Prongay & Murray LLP

8 hours ago Glancylaw.com Show details

Halozyme Therapeutics, Inc. On January 16, 2018, an abstract was published detailing a study of Halozyme’s drug PEGPH20 as a treatment for pancreatic cancer in combination with the cancer drug mFFOX. The abstract’s authors concluded that the addition of PEGPH20 to mFFOX appears to be detrimental, noting that patients who used the

Category: Contact NumberShow more

If You Don’t Buy Halozyme Therapeutics Inc. (NASDAQ: HALO

8 hours ago Stocksregister.com Show details

The number of analysts that have assigned HALO a recommendation rating is 13. Out of them, 1 rate it a Hold, while 11 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged Halozyme Therapeutics Inc. (HALO) as Underweight, while 1 advise Sell.

Category: Contact NumberShow more

HALO WACC % Halozyme Therapeutics GuruFocus.com

5 hours ago Gurufocus.com Show details

As of Dec. 2020, Halozyme Therapeutics's interest expense (positive number) was $20.378 Mil. Its total Book Value of Debt (D) is $399.9075 Mil. Cost of Debt = 20.378 / 399.9075 = 5.0957%. 4. Multiply by one minus Average Tax Rate: GuruFocus uses the latest two-year average tax rate to do the calculation.

Category: Contact NumberShow more

Director, Human Resources Job in San Diego, CA at Halozyme

Just Now Ziprecruiter.com Show details

Design programs drawing from Halozyme corporate strategy, people strategy and Halozyme philosophies for performance, compensation, and leadership; Employee Relations: Lead employee relations initiatives to enhance workforce performance and productivity while aligning with Halozyme's culture. Identify and address people and organizational risk.

Category: Contact NumberShow more

Halozyme Therapeutics Inc Company Profile and News

9 hours ago Bloomberg.com Show details

Company profile page for Halozyme Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information

Category: Contact NumberShow more

Hedge Funds Are Betting On Halozyme Therapeutics, Inc. (HALO)

9 hours ago News.yahoo.com Show details

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is not the most popular stock in this group but hedge fund interest is still above average. Our overall hedge fund sentiment score for HALO is 60.5. Stocks with higher number of hedge fund positions relative to other stocks as well as relative to their historical range receive a higher sentiment score.

Category: Contact NumberShow more

HALO Halozyme Therapeutics Inc. Stock Price & News WSJ

3 hours ago Wsj.com Show details

View the latest Halozyme Therapeutics Inc. (HALO) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Category: Contact NumberShow more

Halozyme To Host Third Quarter 2021 Financial Results

8 hours ago Wfmz.com Show details

(800) 585-8367A telephone replay will be available for two weeks after the call by dialing (800) 585-8367 (domestic callers) or (416) 621-4642 (international callers) using replay ID number 5694076. About Halozyme

Category: Contact NumberShow more

Halozyme Therapeutics, Inc. Common Stock (HALO) Stock

Just Now Nasdaq.com Show details

Halozyme Therapeutics, Inc. Common Stock (HALO) Nasdaq Listed. Nasdaq 100. Data is currently not available. $38.57. +0.39 (+1.02%) DATA AS OF Nov 11, 2021. No Notifications. Add to Watchlist.

Category: Contact NumberShow more

Halozyme Therapeutics's Earnings: A Preview

5 hours ago Finance.yahoo.com Show details

Dividing net income by the total number of shares outstanding yields EPS. Earnings And Revenue. Halozyme Therapeutics EPS is expected to be around $0.53, according to sell-side analysts. Sales

Category: Contact NumberShow more

Manager, External Quality Control Job in San Diego, CA at

8 hours ago Ziprecruiter.com Show details

The Manager, External Quality Control provides a full range of Quality Control (QC) activities supporting Halozyme's ENHANZE programs. The range of functions spans commercial, clinical, and development products and programs in support of our partner relationships and internal programs. The position is pivotal to the execution of Halozyme's

Category: Contact NumberShow more

Halozyme Therapeutics Stock Quote: HALO Stock News, Quotes

1 hours ago Research.investors.com Show details

Halozyme Therapeutics (HALO) Q3 Earnings and Revenues Top Estimates Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 30.95% and 13.63%, respectively, for the quarter ended September 2021.

Category: Contact NumberShow more

HALO Is Its Stock Price A Worthy Investment? Learn More.

3 hours ago Stocknews.com Show details

Revenue growth over the past 12 months for Halozyme Therapeutics Inc comes in at 132.02%, a number that bests 94.74% of the US stocks we're tracking. Stocks that are quantitatively similar to HALO, based on their financial statements, market capitalization, and price volatility, are LGND, PACB, MODN, GWRE, and KLR.

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Brand New Updated

Frequently Asked Questions

What is Halozyme Therapeutics?

( March 2017) Halozyme Therapeutics is an American biotechnology company that develops novel oncology therapies designed to target the tumor microenvironment and licenses a novel drug delivery technology through corporate partnerships. The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California.

Where is Halozyme located?

Halozyme is headquartered in San Diego, California. Halozyme's business is primarily focused on its proprietary and patented recombinant human hyaluronidase enzyme, rHuPH20.

What is argenx’s collaboration with Halozyme?

This collaboration is an example of the value ENHANZE® can potentially bring while a product is still in development where the benefits of subcutaneous administration can be realized earlier by both patients and healthcare providers. argenx represents Halozyme’s ninth global collaboration and license partner for the ENHANZE® technology.

How do I receive the DailyMed drug label update?

DailyMed will deliver this notification to your desktop, Web browser, or e-mail depending on the RSS Reader you select to use. To view updated drug label links, paste the RSS feed address (URL) shown below into a RSS reader, or use a browser which supports RSS feeds, such as Safari for Mac OS X.

Popular Brands

Hms
Holmen
Hyatt